Sanofi to stop marketing Afrezza, citing low Rx
Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.
View ArticleFive things for pharma marketers to know: Wednesday, January 6, 2016
Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza
View ArticleCharacters in DTC Ads Used with Little Reason
Many of the characters we are now meeting do not appear to be directed at a patient insight or purposefully used to de-stigmatize a disease.
View ArticleWhat the AMA's Proposed DTC Ban Overlooks
While DTC advertising does significantly impact consumer demand, most evidence suggests the majority of this demand benefits the overall state of consumer health.
View ArticleBMS CEO defends use of DTC to promote cancer drug
The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."
View ArticleIs This the End of Agency Diversification?
DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
View ArticleThe best and worst celebrity pharma moments
Heaven knows the industry is itself to blame for some of the dopier recurring imagery in its DTC spots, like models clad in white linen riding horses on deserted stretches of beach.
View ArticleCelebrity drug ads: Opportunity or PR disaster?
Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that "regular" ones do not.
View ArticleFive things for pharma marketers to know: Thursday, February 18, 2016
Lawmaker seeks to stop DTC ads for newly approved drugs; testosterone therapy helps sexual function; the FDA requests more data about Catalyst's rare drug
View ArticleOmnicom formalizes health group led by CDM's Wise
The division, dubbed Omnicom Health Group, claims to serve 70% of the top 100 pharma brands.
View Article
